Vrdn-001

4 trials

Filter these 4 trials by condition, phase, country and more.

Open in Search →

4 Registered trials

0 Recruiting

4 Completed trials

1 Sponsors

8 Countries

Phase III

Phase II/III

Phase III: 3 Phase II/III: 1

Indications tested

Endocrine ophthalmopathy 3

Sponsors using this IMP

Viridian Therapeutics Inc. 4

All trials

4 total

A Safety and Tolerability Study of VRDN-001 in Persons with Thyroid Eye Disease (TED) Ended

2023-507563-19-00 Phase III 5 countries Viridian Therapeutics Inc.
An open-label study for participants who are non-responders at the end of treatment assessment on the VRDN-001-101 and VRDN-001-301 pivotal … Ended

2023-507350-33-00 Phase III 8 countries Viridian Therapeutics Inc.
A Safety, Tolerability and Efficacy Study of VRDN-001 in Persons with Chronic Thyroid Eye Disease (TED) Ended

2023-507217-10-00 Phase III 6 countries Viridian Therapeutics Inc.
A multiple ascending dose (MAD) safety, tolerability and efficacy study of VRDN-001, a humanized monoclonal antibody directed against the IG… Ended

2024-512244-36-00 Phase II/III 4 countries Viridian Therapeutics Inc.

Showing 1–4 of 4 trials

← All drugs A–Z